1. Home
  2. ACXP vs PPCB Comparison

ACXP vs PPCB Comparison

Compare ACXP & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Acurx Pharmaceuticals Inc.

ACXP

Acurx Pharmaceuticals Inc.

HOLD

Current Price

$1.52

Market Cap

3.8M

Sector

Health Care

ML Signal

HOLD

PPCB

Propanc Biopharma Inc.

N/A

Current Price

$0.20

Market Cap

3.2M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
ACXP
PPCB
Founded
2017
2007
Country
United States
Australia
Employees
4
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.8M
3.2M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
ACXP
PPCB
Price
$1.52
$0.20
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$143.67
N/A
AVG Volume (30 Days)
48.1K
1.5M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
24.35
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.29
$0.16
52 Week High
$8.34
$10.69

Technical Indicators

Market Signals
Indicator
ACXP
PPCB
Relative Strength Index (RSI) 23.69 33.67
Support Level $0.31 $0.18
Resistance Level $2.89 $0.40
Average True Range (ATR) 0.17 0.03
MACD -0.01 0.01
Stochastic Oscillator 11.39 22.28

Price Performance

Historical Comparison
ACXP
PPCB

About ACXP Acurx Pharmaceuticals Inc.

Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.

About PPCB Propanc Biopharma Inc.

Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.

Share on Social Networks: